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Abstract
Antibody-mediated immunity is highly protective against disease. The majority
of current vaccines confer protection through humoral immunity, but there is
high variability in responsiveness across populations. Identifying immune
mechanisms that mediate low antibody responsiveness may provide potential
strategies to boost vaccine efficacy. Here, we report diverse antibody
responsiveness to unadjuvanted as well as adjuvanted immunization in
substrains of BALB/c mice, resulting in high and low antibody response
phenotypes. Furthermore, these antibody phenotypes were not affected by
changes in environmental factors such as the gut microbiota composition.
Antigen-specific B cells following immunization had a marked difference in
capability to class switch, resulting in perturbed IgG isotype antibody
production. In vitro, a B-cell intrinsic defect in the regulation of class-switch
recombination was identified in mice with low IgG antibody production.
Whole genome sequencing identified polymorphisms associated with the
magnitude of antibody produced, and we propose candidate genes that may
regulate isotype class-switching capability. This study highlights that mice
sourced from different vendors can have significantly altered humoral immune
response profiles, and provides a resource to interrogate genetic regulators of
antibody responsiveness. Together these results further our understanding of
immune heterogeneity and suggest additional research on the genetic
influences of adjuvanted vaccine strategies is warranted for enhancing
vaccine efficacy.
INTRODUCTION
Antibody-mediated immunity provides both short-term
protection from pathogens and long-lived immunological
memory for the lifetime of an organism. The majority of
current vaccines confer protection by stimulating the
production of threshold titers of IgG isotype antibodies.1
However, there is a high degree of heterogeneity in the
antibody response across the human population, with a
proportion of individuals failing to meet protective
thresholds of antibody titers.1 Previous investigations have
established genetic contributors to antibody responsiveness,2,3
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and emerging data illustrates that environmental factors
including the gut microbiota regulate antibody
heterogeneity following immunization.4-8
Antibody production can be elicited via T-dependent
and -independent responses, through cognate antigen
binding to the B-cell receptor.9-14 In a T-dependent
response, activated B cells can differentiate to germinal
center (GC) B cells with provision of signals from pre-T
follicular helper (Tfh) cells and form a germinal center
structure within the lymphoid tissue.15,16 Alternatively,
activated B cells may form an extra follicular antibody
response, a fate shared with B cells eliciting response to T-
independent antigen.17-19 Provision of signals, such as
CD40 and cytokine, induce class-switch recombination
(CSR) within activated B cells.20-22 This switch mechanism
alters the immunoglobulin (Ig) isotype encoded by the B
cell through a unique process of intrachromosomal
deletion, and is critical for the protective antibody response
because of the Ig constant region dictating the effector
function of secreted antibodies.23,24 The resulting class-
switched plasma cells and memory B cells are key to
meeting protective thresholds of antibody titers.25-27
Dysfunction in any of these stages may lead to a low
response phenotype.28,29 A significant understanding of the
mechanisms that regulate antibody production has been
provided by this body of research, yet antibody response
heterogeneity remains an issue for vaccinology, indicating
a gap in our current knowledge of these mechanisms. Thus,
characterizing mediators of antibody responsiveness and
relative contribution toward response magnitude will
determine factors contributing to population heterogeneity
and much needed strategies to boost vaccine efficacy.
We observed that BALB/c substrains from different
commercial suppliers (herein referred to as BALB/c A
and BALB/c B) had diverse antibody profiles in response
to seasonal trivalent influenza vaccine as well as
immunization with NP-OVA adjuvanted with incomplete
Freund’s adjuvant (IFA). The examination of the stages
of antibody generation following immunization
demonstrated Tfh cells and class switching (C-S) within
GC B cells were severely perturbed in low antibody
responder BALB/c A mice. We established that this C-S
defect was B-cell intrinsic, shared across CD40 and TLR
stimulation pathways and was specific to CSR. Whole
genome sequence analysis elucidated polymorphisms in
known CSR genes, but a lack of a predicted effect of
these polymorphisms on protein activity suggest a role
for new or unappreciated regulators of antibody
responsiveness in low-responder BALB/c A mice. These
mice and genome sequence data provide a resource to
potentially identify new candidates for the development
of immune-adjuvant tools to boost antibody titers to
threshold levels required for vaccine efficacy.
RESULTS
Divergent antibody responses in substrains of BALB/c
mice
There is mounting evidence that the substrains of mice
from different sources have profoundly distinct immune
responses, and these immune phenotypes may be
influenced by both genetic and environmental factors.30-35
We sought to examine vaccine-induced antibody
responsiveness in this context with BALB/c mice bred in
our facility, but originally obtained from different
suppliers. Following immunization with trivalent influenza
vaccine, BALB/c A had a significantly attenuated trivalent
influenza vaccine-specific IgG1 response as compared to
BALB/c B (Figure 1a). We next investigated the response
to NP-OVA in IFA, and BALB/c A mice produced
significantly lower NP-specific and total IgG1, IgG2a and
IgE antibodies following adjuvanted immunization
(Figure 1b, c). These data establish that the substrains of
BALB/c mice exhibit low- and high-titer antibody
responses, with BALB/c A mice possessing a low-
responder phenotype to both unadjuvanted and
adjuvanted immunization strategies. We next investigated
whether antinuclear antigen-specific antibody titers were
elevated in 24-week-old mice, as a surrogate marker of
potential autoimmune responses. Antinuclear antigen-
specific antibody levels in both substrains of BALB/c mice
were below the reactive serum threshold of the assay
(>50 U mL1), suggesting the high response in BALB/c B
mice was not linked to an autoimmune phenotype (data
not shown).
Antibody responses are not affected by manipulation of
the microbiota in adulthood
To evaluate the variability in gut microbiota between the
substrains of BALB/c mice, we employed 16S ribosomal
RNA sequencing. The fecal gut microbiota composition
observed was substantially different between the BALB/c A
and BALB/c B substrains (Figure 2a). However, the level
of richness and diversity of the microbial communities
were comparable (data not shown). To determine the
influence of microbiota composition on antibody response
phenotype, a substantial alteration in microbial
composition was induced using the established method of
cohousing.34,36 Cohousing resulted in a marked shift in
gut microbial composition in both BALB/c A and BALB/c
B cohoused mice (BALB/c ACH and BALB/c BCH,
respectively), demonstrating cohousing resulted in
horizontal microbial transfer (Figure 2a, b). Despite the
similar taxonomic profile in ACH and BCH after
cohousing, the function of these microbiomes may still be
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disparate.37 To investigate the microbiota influence on
antibody response capability, ACH is compared to BALB/c
A, and BCH to BALB/c B, as a marked shift from the same
starting composition has been induced. In response to
immunization with NP-OVA in IFA, cohousing was not
sufficient to alter NP-specific IgG1, IgG2a and IgE
antibody responses in BALB/c ACH as compared to
BALB/c A mice (Figure 2c), or BALB/c BCH antibody
responses compared to BALB/c B mice (Figure 2d).
Moreover, housing mice in the same cage can control for
other environmental variables in addition to microbial
transfer, thus allowing us to eliminate the influence of
other environmental variables on the antibody response.
As environmental effects did not influence immunization-
induced antibody production, these data suggest the
antibody response capability is genetically regulated in
both substrains of BALB/c mice.
Altered capability of B cells to undergo isotype class
switch in low-responder BALB/c A mice
To determine the mechanisms resulting in the diverse
antibody responsiveness, we initially assessed B-cell
frequencies in multiple tissues under homeostatic conditions.
B-cell frequencies in spleen, bone marrow and lymphoid
tissues, and frequencies of B-1, marginal zone and follicular
B-cell subsets within the spleen were all comparable between
the substrains of BALB/c mice, suggesting no defects in
hematopoiesis or B-cell homeostasis in low-responder
BALB/c A mice (Supplementary figure 1). We then tracked
the formation of the T-dependent B-cell response after
immunization with NP-OVA in IFA. GC structure in the
draining lymph nodes was comparable between substrains
(Figure 3a), and a similar frequency of GC structures were
observed (Figure 3b). Serum titers of NP-specific IgM were
also comparable; however, NP-specific IgG1 titers were
significantly reduced in BALB/c A mice (Figure 3c, d). The
development of the NP-specific B-cell response was also
tracked using flow cytometry. No difference in the numbers
of NP-specific GC B cells induced by BALB/c A and B mice
was observed, correlating with comparable formation of GC
structure observed by imaging (Figure 3e). Of these NP-
specific GC B cells, a similar frequency of IgM isotype was
also observed (Figure 3f). However, a reduced frequency of
NP-specific GC cells were of class-switched IgG1 isotype in
BALB/c A, meaning numbers of IgG1+ NP-specific GC B
cells were significantly reduced in low-responder BALB/c A
mice (Figure 3g–i). Similarly, the generation of IgG2a+ GC B
cells in BALB/c A was also reduced (Supplementary figure
2a, b). Taken together, these data indicate BALB/c A mice
develop NP-specific GC B cells and mount an antigen-
specific IgM antibody response comparable to BALB/c B
mice. Conversely, the fate of isotype switched responding B-
cell populations is significantly skewed, leading to reduced
NP-specific IgG1, IgG2a and IgE isotypes in BALB/c A mice.
Fewer NP-specific plasma cells were detected in the
draining lymph nodes of BALB/c A mice (Supplementary
figure 2c). Additionally, a higher proportion of the NP-
specific plasma cells were IgG1 isotype in BALB/c B as
compared to BALB/c A, whereas BALB/c A possessed a
higher proportion of IgM isotype as compared to BALB/c
B (Supplementary figure 2d, e). This resulted in
significantly fewer IgG1+ NP-specific plasma cells in the
draining lymph nodes of BALB/c A (Figure 3j). Long-
lived plasma cells migrate to the bone marrow soon after
differentiation and so the frequency of C-S plasma cells
was assessed in this compartment.20 A significantly
reduced number of IgG1+ plasma cells were observed in
low-responder BALB/c A mice (Figure 3k). Affinity
maturation is a fundamental process within the GC to
select high affinity B cells,38 and these high affinity B
cells receive enhanced Tfh-derived C-S signals.39
Figure 1. Antibody responsiveness of BALB/c mice from different sources. (a) BALB/c A and BALB/c B mice were vaccinated subcutaneously with
trivalent influenza vaccine and trivalent influenza vaccine-specific IgG1 titers were measured 28 days after immunization by ELISA. BALB/c A and
BALB/c B mice were vaccinated subcutaneously with NP-OVA + IFA and (b) NP-specific IgG1, IgG2a and IgE and (c) total IgG1, IgG2a and IgE
serum titers measured 14 days after immunization by ELISA. Data points represent individual mice and heights of the bar represent the median.
Dashed lines represent lower limit of sensitivity, set at blank OD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. Data are
representative of at least two experiments.
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Figure 2. Microbiota composition does not regulate altered antibody responsiveness in BALB/c A and BALB/c B mice. BALB/c A and BALB/c B mice
were cohoused to promote microbiota transfer and 4 weeks later vaccinated with NP-OVA in IFA; cohoused BALB/c A (ACH), BALB/c B (BCH), BALB/c
A and BALB/c B. Gut microbiota composition was determined with taxonomic profiling of fecal bacterial communities from 16s rRNA sequencing.
(a) Relative abundance at the phyla level with key populations-of-interest highlighted at the order, family or genus level and (b) principal
component analysis of fecal microbiota composition; left and right plot provide two views of the taxonomic diversity. Samples taken 1 day prior to
immunization (n = 5 per group). NP-specific IgG1, IgG2a and IgE titers in serum of (c) ACH and BALB/c A and NP-specific IgG1, IgG2a and IgE titers
in serum of (d) BCH and BALB/c B 14 days after immunization with NP-OVA in IFA. Data points represent individual mice and heights of the bar
represent the median. Dashed lines represent lower limit of sensitivity, set at blank OD. Data are representative of at least two experiments.
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Therefore, reduced C-S in BALB/c A may be a result of
perturbed affinity maturation. We examined the affinity
of NP-specific antibodies as a readout of affinity
maturation efficiency; a small but significant difference in
NP-specific IgG1 affinity was observed between the
substrains (Supplementary figure 2f). These results
demonstrate that the reduced capability of low-responder
BALB/c A GC B cells to undergo productive C-S leads to
reduced antigen-specific IgG plasma cells forming from
the GC response, which in turn infers the altered
magnitude of the immunization-induced class-switched
antibody response.
Altered capability to mount an appropriate Tfh-cell
response in low-responder BALB/c A mice
Tfh are a crucial for optimal GC B-cell responses,
coordinating selection and maintenance of high affinity
GC B-cell clones; therefore, we investigated the frequency
and activity of the Tfh-cell subset in the substrains.40 The
number of Tfh cells induced in response to NP-OVA in
IFA immunization was significantly reduced in low-
responder BALB/c A (Figure 4a), and the expression of the
Tfh-cell lineage-specific transcription factor Bcl6 and
critical B-cell–stimulatory signals were also reduced
Figure 3. Germinal center B cells from low-responder BALB/c A mice possess a reduced class-switch capability. BALB/c A and BALB/c B mice
were vaccinated subcutaneously with NP-OVA + IFA. Draining lymph nodes and serum were taken 14 days after immunization. (a) Formation of
GC structures was visualized by immunofluorescence imaging; Cyan: GL7, Green: CD4, Magenta: B220. Representative images of one mouse per
group. Scale bar 500 lm. (b) The number of GL7+ cell clusters within the B-cell follicle counted per section. (c) NP-specific IgM and (d) IgG1
serum titers measured 14 days after immunization by ELISA. (e) Number of NP+ GC B cells in the lymph node. (f) Frequency of NP+ IgM+ GC B
cells in the lymph node. (g) Dot plots illustrate IgG1 expression and NP-specificity within the GC B-cell population; pre-gated on size, viability
CD138– B220+ GL7+ CD38–. Representative dot plots of one mouse per group. (h) Frequency and (i) number of NP+ IgG1+ GC B cells in the
lymph node. (j) Number of NP+ IgG1+ plasma cells in the lymph node; gated on size, viability CD138+ B220–. (k) Number of IgG1+ plasma cells
in the bone marrow 28 days after immunization with OVA adjuvanted with alum; gated on size, viability CD138+ B220–. Data points represent
individual mice and heights of the bar represent the median. Data are representative of at least three experiments.
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(Figure 4b). These data suggest Tfh-cell activity may also
be diminished in low-responder BALB/c A mice. T
follicular regulatory (Tfr) cells have previously been
shown to control the Tfh-cell response.40 However,
numbers of Tfr cells were significantly reduced in low-
responder BALB/c A mice, indicating Tfr cells were
unlikely to be causative of the attenuated Tfh-cell
frequency in this substrain (Figure 4c). To ascertain
whether the difference in the Tfh-cell response was specific
to this CD4+ T-cell subset, the differentiation of central
and effector memory CD4+ T-cell subsets induced in
response to NP-OVA in IFA immunization was assessed
and found to be comparable between the substrains
(Figure 4d). Numbers of CD4+ T cells in the lymph nodes
and spleen were also equivalent under homeostatic
conditions (Supplementary figure 3). Furthermore, na€ıve
CD4+ T cells were equally able to respond to polyclonal
activation in vitro (Figure 4e). These results suggest the
difference in the Tfh-cell response is specific to this CD4+
T-cell subset and not due to dysfunction of the CD4+ T-
cell compartment as a whole.
Diminished capability of low-responder BALB/c A B
cells to class switch when stimulated through TLR or
CD40 in vitro
We performed quantitative analysis of na€ıve B cells
stimulated in vitro to establish whether the altered CSR
Figure 4. Tfh response capability is altered in low-responder BALB/c A. (a) The number of Tfh cells within draining lymph nodes 14 days after
NP-OVA + IFA immunization was determined by flow cytometry. Tfh gated on size, viability CD3+CD4+CXCR5+PD-1+FOXP3–. (b) Tfh cells were
sorted from draining lymph nodes 7 days after immunization and expression of Bcl6, Cd40l, Il21 and Il4 determined by qRT-PCR. The relative
expression of each target to 18S is presented, calculated relative to BALB/c A responsiveness that is set at 1. (c) Number of Tfr cells and (d)
central memory and effector memory CD4+ T cells within draining lymph nodes 14 days after NP-OVA + IFA immunization was determined by
flow cytometry. CD4+ T cells gated on size, viability CD3+CD4+; Tfr: CXCR5+PD-1+FOXP3+, central memory: CD62L+CD127+CD44+ and effector
memory: CD62L–CD127+CD44+. (e) In vitro proliferation of na€ıve CD4+ T cells in response to aCD3, aCD28 and IL-2 stimulation. Data points
represent individual mice and heights of the bar represent the median. Data are representative of at least three experiments.
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capability was driven by a B-cell intrinsic mechanism.
Lipopolysaccharide (LPS) + interleukin (IL)-4 induces B-
cell activation and IgG1 production.21,41,42 Viability as
measured by total live NIRTM viability stain negative cell
numbers at 24 h (Figure 5a) was equivalent between B
cells from both mice, demonstrating differences in
survival in the context of T-independent stimulation
(LPS + IL-4) do not account for the difference in
antibody responsiveness. Strikingly, IgG1 class switching
was significantly reduced in low-responder BALB/c A B
cells despite equivalent proliferation profiles (as measured
by dilution of division tracking dye) in B cells of BALB/c
A and B (Figure 5b). C-S is regulated by division number
and cannot occur after commitment to differentiated
CD138+ plasma cells. For this reason, by altering the
generation in which C-S occurs (or conversely that
plasma cell differentiation begins), there can be a
profound effect on the capability of B cells to C-S.43
Therefore, we compared the kinetics of IgG1 C-S and
plasma cell differentiation in B cells from the BALB/c
substrains. Although the frequency and number of IgG1+
cells within each generation is significantly reduced in
low-responder BALB/c A B cells (Figure 5b), the
distribution of IgG1-switched B cells across generation
number was equivalent. These data demonstrate that C-S
kinetics were comparable (Supplementary figure 4a). The
frequencies of PCs in generations three to five were
slightly greater in BALB/c A (Supplementary figure 4a).
However, no difference in distribution of the total plasma
cell population across generations was seen between the
substrains, indicating plasma cell differentiation is
initiated and progresses equivalently in both substrains
(Supplementary figure 4b, c). In summary, C-S
differentiation of plasma cells were comparable,
suggesting the capability to C-S is not influenced by
differences in the kinetics of B-cell responses.
Crosslinking CD40 using soluble aCD40 antibody IC10
acts as an in vitro mimic of T-dependent activation, and
in combination with IL-4 stimulates C-S to IgG1.44 IgG1
C-S in low-responder BALB/c A B cells was reduced
despite similar proliferation of the B cells in both
substrains (Figure 5c). The B cells from low-responder
BALB/c A class switch to a greater frequency in response
to aCD40 + IL-4 stimulation as compared to LPS + IL-4
stimulation (Figure 5b, c). Previous investigations have
shown a greater dependence on IL-4 signaling to induce
IgG1 C-S following aCD40 stimulation,45 and the
increased response to this stimulation in low-responder
BALB/c A B cells may suggest a potential dysfunction
within the IL-4 signaling pathway in this substrain. To
assess whether differences in the antibody response were
dependent purely on the IL-4 pathway, B cells were
stimulated with LPS alone and C-S to IgG3 isotype was
assessed. Again, proliferation was equivalent between B
cells from the substrains. However, C-S to IgG3 was
significantly reduced in low-responder BALB/c A B cells
(Figure 5d), demonstrating an intrinsic alteration in CSR
in BALB/c A mice that is IL-4 signaling pathway
independent. These results suggest differences in antibody
responses are restricted to a deficiency in CSR, as the
proliferation and differentiation of B cells from BALB/c A
and BALB/c B mice are equivalent to both T-dependent
and -independent stimuli. Finally, mice were immunized
with NP-ficoll to assess T-cell-independent C-S capability
in vivo. The generation of IgG3 antibody was
significantly reduced in low-responder BALB/c A mice
(Supplementary figure 4f), further indicating B cell-
intrinsic regulation of the capability to undergo CSR.
Identification of genetic polymorphisms that associate
with aberrant antibody responsiveness
A whole genome sequencing approach was used to
identify genetic polymorphisms that may affect the
mediators or regulators of the CSR mechanism in BALB/c
A mice. Initially, polymorphisms specific to BALB/c A
and BALB/c B were identified (Figure 6a) and a list of
variant genes specific to BALB/c A and BALB/c B created
through gene assignment to these polymorphisms
(Supplementary table 3). We then selected from the list of
variant genes specific to BALB/c A, those genes with a
known role or ontology linked to the regulation or
mechanism of CSR and confirmed their expression in
mature B cells using the ImmGen database23,45-48
(Supplementary table 4). A total of 34 gene targets were
identified (Figure 6b), and each polymorphism was then
interrogated for a predicted effect on protein activity. The Ets1
polymorphism was predicted to influence Ets1-007 noncoding
mRNA, which could potentially affect Ets-1 protein
expression. The Commd1 insertion mutation was predicted to
alter regulation of the Commd1-001 transcript based on its
location the 50 UTR of this transcript. Additionally, we
determined that the 14 intronic polymorphisms we had
identified had no predicted effect on splicing.
Next, the influence of polymorphism on transcription
factor binding sites was predicted using Transfac. The
deletion in the regulatory region of protein phosphatase 2,
regulatory subunit B, beta (Ppp2r2b) was predicted to
result in the loss of three Sox-4 binding sites, which would
likely reduce the transcription of Ppp2r2b as Sox4 is
upregulated in activated B cells.49 It was predicted that the
insertion mutation within the regulatory region of
neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2)
would result in the addition of a Sox-4 transcription factor
45
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binding site, possibly upregulating its transcription. A
deletion in the guanine nucleotide-binding protein (G
protein), gamma 4 (Gng4) regulatory region, was predicted
to result in the loss of a Trf1 and RREB1 transcription
factor binding site, which may reduce Gng4 transcription.
Fifteen further intergenic variants were identified but were
not predicted to affect gene activity using our methods.
These data propose putative targets in genetic regulation of
low antibody responsiveness, and serve as a resource to be
mined in the future as more CSR regulators are recognized.
Furthermore, the genomic sequences of these two BALB/c
A substrains offer a resource for identifying unappreciated
regulators of antibody responsiveness through untargeted
analytical methods.
DISCUSSION
In this study, we explored the mechanisms associated with
altered antibody responses in substrains of BALB/c mice.
We hypothesized this would further our understanding of
the factors that influence the heterogeneity of protective
antibody titers observed in the human population. Despite
the mice harboring dramatically different microbiota
compositions, cohousing conferred no alteration on
response magnitude. These data indicate that genetic
regulation is dominant over environmental influence on
antibody responsiveness in these mice. Immunization
responsiveness was determined by efficiency of C-S in GC
B cells, which was paralleled by altered Tfh activity. Critical
to this study was the identification of a B-cell intrinsic
dysfunction in CSR capability, which was downstream of
CD40 and TLR stimulation pathways. This led to the
targeted identification of polymorphisms in known
regulators or mediators of CSR to elucidate candidate
genes that confer the altered immune responsiveness
observed between these mice.
It is known that both gene composition and
environmental conditions can impact immune responses
in mice.6,32-35,50,51 As expected, the gut microbiota
composition was substantially different between the
substrains of BALB/c mice, but the lack of effect of
cohousing on antibody production in either low or high
responder BALB/c mice suggests neither the gut microbiota
nor other environmental variables were sufficient to drive
the antibody responder phenotypes in these mice. Previous
findings have demonstrated a lack of microbial regulation
in antibody responses induced by adjuvanted vaccines;
here, we extend these findings to demonstrate a genetic
regulation drives the response capability of these substrains
of BALB/c mice.6 However, discordant with our results are
recent studies demonstrating a dominant role of
environment in the regulation of antibody responsiveness
in the human population.8,52 The discrepancy with our
findings may be due to the different ways in which these
studies characterized antibody responsiveness. One study
assessed influenza-specific responses induced by diverging
frequency and forms of unadjuvented antigen exposure,
whereas another correlated total antibodies raised against a
multitude of immune challenges. Moreover, in both cases,
exposures were over the lifetime of the individual, during
which multiple parameters, including age, will impact
response magnitude.8,52 In turn, our study is a controlled
assessment of response capability, measuring antibody
magnitude amounted to one adjuvanted antigen exposure.
The discrepancy in these data suggest investigations aimed
at understanding the relative contribution of environmental
and genetic influences on response capability to adjuvanted
vaccines and how response capability shapes heterogeneity
within populations warrant further investigation. Moreover,
it demonstrates microbiota-targeted approaches to adjuvant
immune capability will not be effective in individuals with
similar genetic dysfunctions to that observed in low-
responder BALB/c A mice, and suggests immune-adjuvant
approaches may have a broader success rate over a
population.
Low-responder BALB/c A mice have a perturbed B-cell
C-S capability resulting in a significant reduction in
immunization-induced IgG1, IgG2a and IgE antibody
production. Results gained from the in vitro stimulation of
na€ıve B cells determined equivalent activation and
proliferative capabilities of B cells from both substrains, as
well as matched C-S and plasma cell differentiation kinetics.
However, the capability to undergo CSR to IgG1 and IgG3
was affected in low-responder BALB/c A mice, suggesting a
Figure 5. Isotype class switching is defective in BALB/c A B cells. Na€ıve splenic B cells of BALB/c A and BALB/c B mice were stimulated with LPS +
IL-4 and monitored for (a) survival at 24 h and (b) C-S to IgG1 and proliferation at 90 h by flow cytometry; graphs show the frequency and
number of IgG1+ cells in each generation gated on size, viability B220+ CD138+ CTV IgM– IgG1+. (c) Na€ıve splenic B cells were stimulated with
aCD40 + IL-4 and monitored for proliferation and C-S to IgG1 at 90 h by flow cytometry; graphs show the frequency and number of IgG1+ cells
in each generation gated on size, viability B220+ CD138+ CTV IgM– IgG1+. (d) Na€ıve splenic B cells were stimulated with LPS and monitored for
proliferation and C-S to IgG3 at 90 h by flow cytometry; graphs show the frequency and number of IgG3+ cells in each generation gated on
size, viability B220+ CD138+ CTV IgM– IgG3+. (a) Each data point represents one sample. (b–d) Representative dot plots from one sample per
group and data from triplicate cultures were graphed. Statistical significance was determined using an unpaired t-test. Data are representative of
at least three experiments.
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genetic dysfunction afflicts a B-cell intrinsic regulator or
mediator of CSR. Low-responder BALB/c A mice were able
to mount a sufficient GC B-cell response and appropriate
IgM production. However, subsequent isotype class-switch
responses were skewed, leading to significantly reduced
IgG1, IgG2a and IgE responses in BALB/c A. As there are no
known markers for selection of GC B cells in this transition
state, we are unable to characterize the isotype expression
profile of this responding population. The Tfh response was
also reduced in low-responder BALB/c A mice indicating
that the pathways in the generation of the antibody
response, in addition to CSR, are also deficient in BALB/c
A. Further investigation is required to determine whether
perturbation in Tfh responsiveness and CSR capability are
regulated by shared or distinct polymorphisms, and indeed
if other immunological mechanisms are also affected.
Toward the development of immune-adjuvant therapeutics,
determining the relative contribution that CSR efficiency
and Tfh responsiveness impart to the magnitude of
antibody response capability could provide valuable insight
to whether therapeutic targeting of just one dominant
pathway would be sufficient to boost responsiveness, or
whether multiple pathways in antibody generation need to
be targeted in unison.
The observation that at least some B cells from low-
responder BALB/c A mice retained the capability to class
switch suggests the genetic dysfunction afflicts protein
activity of a C-S regulator. Moreover, altered C-S
capability after stimulation through both TLR and CD40
demonstrates the C-S regulator lies downstream of
multiple stimulation pathways and therefore may be a
mediator of the CSR mechanism after these pathways
converge, or alternatively, it is shared across multiple
pathways. Intriguingly, we noted that B cells from low-
responder BALB/c A mice had a greater capacity to
undergo C-S in response to CD40 stimulation compared
to TLR ligands. This suggests that the functional class-
switch B-cell polymorphisms we observed could be more
pervasive following T-cell–dependent stimuli, and
germinal center responses. Thus, deciphering the origin
of this difference could identify promising adjuvant
candidates for improving antibody responses in vivo.
Identification of dysfunctional genetic elements in the
C-S mechanism utilizing differential gene expression
analysis was deemed unfeasible in the absence of a method
to positively isolate cells actively undergoing class
switching. Instead, investigation of genetic polymorphisms
affecting known regulators or mediators of CSR from
whole genome sequence data was performed to elucidate
genetic control of the altered C-S capability of these
substrains. Polymorphisms in BALB/c A mice were
interrogated as it was deemed likely to be the deviant
substrain given the perturbed C-S capability is at odds to
Figure 6. Identification of genetic polymorphisms that associate with
altered capability to class-switch in low-responder BALB/c A mice. (a)
The number of SNP and INDEL polymorphisms to the mouse
reference genome that are specific to BALB/c A or BALB/c B
respectively. (b) BALB/c A candidate genes compiled by identification
of polymorphisms in known mediators or regulators of CSR. CDS,
coding sequence; nCDs, non-coding sequence; RR, regulatory region.
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the expected antibody response capability of BALB/c
mice.53 Four candidates with the greatest potential to
confer the perturbed C-S response capability of low-
responder BALB/c A mice were identified. Altered Ets1
activity has the potential to regulate C-S to all antibody
isotypes, as Ets1 binds to the regulatory region 30 to Igha
controlling germline transcription of all switch regions.47
Ets1 has previously been shown to be critical only for C-S
to IgG2a and not IgG1, IgG2b or IgG3 isotype switching
using an Ets-1/ chimera approach, which is at odds
with reduced C-S to all isotypes observed in low-
responder BALB/c A.54 However, altered protein activity
may induce a different effect on C-S as compared to
protein absence as was modeled with the Ets-1/ mice,
and therefore, Ets1 remains a strong candidate for
conferring the BALB/c A class-switch phenotype. The
other three key candidate polymorphisms are all located
in regulatory regions of phosphatylinositol 3-kinase
(PI3K) signaling mediators. PI3K-Akt signaling controls
activation-induced cytidine deaminase expression and GC
B-cell phenotype through tight regulation of forkhead box
O proteins (FOXO), with enhanced PI3K-Akt signaling
inhibiting FOXO activation of activation-induced cytidine
deaminase-driven C-S.55 The polymorphisms affecting
Ppp2r2b and Ntrk2 act to enhance PI3K-Akt signaling
and thus potentially suppress FOXO-driven activation of
activation-induced cytidine deaminase and C-S in BALB/c
A. The final candidate Gng4 is a mediator of CXCR4
signaling to the PI3k-Akt pathway;56 however, recent
demonstration that CSR capability is intact in CXCR4/
GC B cells would challenge the potential impact of this
polymorphism.57 Notably, the lack of clear support for
any of these four candidates as likely mediators of the
low-responder phenotype in BALB/c A mice indicates
that a unique or previously unappreciated regulator of
the CSR mechanism may perturb C-S capability in
BALB/c A B cells. It is also possible that epigenetic
regulation may play a role; therefore, the validation that
known mediators or regulators of CSR are not perturbed
in this way is imperative.58 In addition to the perturbed
response in BALB/c A mice, it remains to be determined
whether SNPs in BALB/c B mice may alternatively
confer a heightened antibody response. These results
demonstrate that although we have sound understanding
of the T- and B-cell mechanisms that regulate antibody
responsiveness, there are still gaps in our knowledge
regarding genetic mechanisms controlling C-S capability.
In summary, this study has identified a B-cell intrinsic
genetic dysfunction that perturbs antibody response capability.
These investigations are timely, given the recent data
supporting a stronger role for environmental influences on B-
cell responses and antibody production.4,8,52,59 These
discrepancies may well be resolved when immune-adjuvant or
microbiota-targeted approaches to boost antibody
responsiveness in the human population are compared across
both unadjuvanted and adjuvanted vaccine responses.6 Based
on a lack of clear genetic polymorphisms in known CSR
candidate genes in low-responder BALB/c A mice, we
attribute this altered antibody response capability to a
potentially novel or previously unappreciated regulator of
CSR. This study also provides a genome sequence resource
that could be exploited to identify this unknown regulator,
and potentially elucidate polymorphisms shared with low
responders in the human population. If successful, low-
responder BALB/c A mice will be a useful tool to explore
new immune adjuvants to augment antibody
responsiveness and boost vaccine efficacy.
METHODS
Mice, cohousing and bone marrow chimeras
Specific pathogen-free BALB/c (BALB/c A) were originally
imported to the Malaghan Institute from the Animal Resources
Centre, Murdoch, Australia in January 2010 and BALB/c By
(BALB/c B) were originally imported to the Malaghan Institute
from the Jackson Laboratories, Bar Harbour, Maine, USA, in
May 2011. Mice were bred and housed at the Malaghan
Institute of Medical Research Biomedical Research Unit and
were utilized for this study between December 2013 and March
2017, with BALB/c A in generation N18 and BALB/c B
generation N11 at time of completion of all experiments. Age-
and sex-matched mice were used at 6–8 weeks of age unless
otherwise indicated. To promote microbiota transfer in
specified experiments, 4-week-old mice were cohoused for
4 weeks prior to immunization. Fecal samples were collected
after 4 weeks of cohousing and mice were vaccinated the day
after fecal sample collection. Cohousing was maintained for a
further 2 weeks until the endpoint of the experiment.
Infections and immunizations
Immunizations were administered subcutaneously. IFA (Sigma-
Aldrich, Auckland, New Zealand) was formulated at 1:1 volume
with 50 lg of ovalbumin (OVA; Sigma-Aldrich) or NP-OVA
[4-hydroxy-3-nitrophenyl (acetyl coupled to OVA); Biosearch
Technologies, Novato, CA, USA] in phosphate buffered saline.
In place of IFA, 1 mg of Alum was used in specified experiments
(Alu-gel-S, Serva Electrophoresis GmbH, Heidelberg,
Germany). Unadjuvanted trivalent seasonal influenza vaccine
(Influvac, AbbotBiologicals, Macquarie Park, Australia) was
used at 1:10 of the human dose.
Enzyme-linked immunosorbent assay
Commercial kits were used to quantify total serum IgG1
(eBioscience, San Diego, CA, USA), IgG2a (eBioscience), IgE
(BD Biosciences, San Jose, CA, USA) and antinuclear antigen
antibodies; IgG, IgA and IgM reactive to DNA, SSA/Ro, SSB/
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La, Scl70, Sm, RNP, Jo-1 (Alpha Diagnostic International, San
Antonio, TX, USA). Antibodies used in noncommercial
ELISAs are listed in Supplementary table 1. Serum NP-specific
antibody levels were determined with NP coupled to bovine
serum albumin (NP-BSA; Biosearch Technologies) for capture
followed by biotinylated anti-mouse IgG1, IgG2a, IgE or IgM
detection. Plates were then incubated with streptavidin-HRP
(Biolegend, San Diego, CA, USA), followed by TMB substrate
(BD Biosciences) for colorimetric development. Plates were
analyzed at 450 nm and graphs display the total OD450
reading with a dotted line representing background.
Cell isolation
Single cell suspensions were prepared from the lymph nodes,
spleens and bone marrow by mechanical disruption and
passage through a 70-lm nylon strainer (BD Biosciences). Red
blood cell lysis of splenocytes was performed with tris-buffered
ammonium chloride for 5 min at room temperature.
In vitro cell culture
Purified B cells were isolated following a previously described
method.44 Briefly, purified B cells were isolated for in vitro
stimulation from RBC-lysed splenocytes first separated by a
density step gradient of 50, 65 and 80% Percoll PLUS (Sigma-
Aldrich) diluted with phosphate buffered saline. Cells at the 65
and 80% interface were collected and B cells isolated using the
MACS B cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany). Purified B cells were cultured at 2 9 105 cells mL1
in Iscove’s modified Dulbecco medium + GlutaMAX (Sigma-
Aldrich) supplemented with fetal bovine serum (Sigma-Aldrich),
penicillin/streptomycin (Sigma-Aldrich) and b-mercaptoethanol
(Sigma-Aldrich) with or without stimulants; LPS (L2654; Sigma-
Aldrich) 15 lg mL1, IL-4 (generated from CHO-IL4 hybridoma
cells) 1000 U mL1 and recombinant IL-5 (Biolegend)
1000 U mL1. CD4 T cells were isolated from mesenteric lymph
nodes using the MACS CD4 T cell isolation kit (Miltenyi Biotec)
and cultured in Iscove’s modified Dulbecco medium plus
GlutaMAX (Sigma-Aldrich) supplemented with fetal bovine
serum (Sigma-Aldrich) and penicillin/streptomycin (Sigma-
Aldrich), with the addition of anti-CD28 (generated from 37.51
hybridoma cells) with or without IL-2, 100 U mL1 (Proleukin,
Chiron, Emeryville, CA, USA). Cells were plated at
2 9 105 cells mL1 in 96-well plates coated with 10 lg mL1
anti-CD3 (generated from 2C11 hybridoma cells).
Antibodies and flow cytometry
Cells were stained with zombie NIRTM fixable viability stain
(Biolegend) at 4°C for 10 min to identify dead cells. Cell surface
antibodies and anti-mouse CD16/32 (generated from 24G2
hybridoma cells) were diluted in phosphate buffered saline with 2%
fetal bovine serum and incubated at room temperature for 30 min.
The FoxP3 fixation and permeabilization buffer set (eBioscience)
was used when staining for intracellular markers. Antibodies and
anti-mouse CD16/32 were diluted in permeabilization buffer and
incubated at room temperature for 30 min. To assess proliferation,
5 x 105 cells mL1 were stained with CellTrace Violet (Life
Technologies) for 4 min at 37°C. Staining was stopped by the
addition of fetal bovine serum and cells washed four times in
Iscove’s modified Dulbecco medium supplemented with fetal
bovine serum (Sigma-Aldrich). Samples were acquired on an LSRII
or Fortessa cytometer (BD Biosciences) linked to FACSDIVA
software (BD Biosciences) and analyzed with Flow Jo v9 (Tree Star
Inc, CA, USA). In sorting experiments, cells were isolated using a
FACSVantage (BD Biosciences) linked to FACSDIVA software (BD
Biosciences). Antibodies used for flow cytometry including cell
sorting are listed in Supplementary table 1.
Immunohistochemistry
Antibodies used for immunohistochemistry are listed in
Supplementary table 1. Lymph nodes were snap frozen in OCT
Tissue-Tek OCT compound (Sakura Finetek, the Netherlands).
Six 5-lm frozen sections per sample were taken from the efferent
lymph vessel at an interval of 50 lm. Follicular B cells were
detected with B220 and germinal center B cells detected with GL7.
The T-cell zone was visualized with CD4. Stained sections were
mounted with KPL fluorescent mounting media (Gaithersberg,
MD, USA) and analyzed with a laser-scanning Olympus FV1200
confocal microscope (Tokyo, Japan) using a 109 objective.
Quantitative real-time PCR
RNA was isolated from sorted cells using the Arcturus Picopure
RNA Isolation Kit (Applied Biosystems, Foster City, CA, USA)
following the manufacturer instructions. Briefly, cells were sheared
with a needle then lysed in extraction buffer at 42°C, the
supernatant containing extracted RNA was then loaded onto RNA
purification columns, washed and eluted in 20 lL of RNAse-free
water. RNA was converted to cDNA using the High-capacity
cDNA Reverse Transcription Kit (Applied Biosystems) following
the manufacturer’s instructions. Quantitative real-time PCR was
performed with specific Taqman primers (Life Technologies) and
the Taqman fast Universal PCR master mix (Applied Biosystems)
on the QuantStudio 7 flex platform (Life Techniologies). Primers
used for qRT-PCR are listed in Supplementary table 2.
16s ribosomal RNA Illumina sequencing and analysis
For microbiota profiling, genomic DNA was extracted from
fecal pellets using the DNA mini stool kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. Briefly,
each fecal sample was lysed with proteinase K and lysis buffer
at 70°C, and the lysed suspension was then loaded onto a
QIAmp spin columns, washed and eluted in 100 lL of
RNAse-free water. DNA yield was assessed using the
QuantusTM fluorometer (Promega, Madison, WA, USA), and
DNA quality was measured with the Nanodrop ND-1000
spectrophotometer (Thermofisher, Waltham, MA, USA).
Amplification of the V3–V4 regions of the 16S rRNA gene
followed by 2 9 250 bp sequencing on the MiSeq platform
was performed at NZ Genomics Ltd (NZGL) using the
standard Illumina method (Amplicon PCR primers IP of
Illumina) https://support.illumina.com/content/dam/illumina-
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support/documents/documentation/chemistry_documentation/
16s/16s-metagenomic-library-prep-guide-15044223-b.pdf.
Amplicon sequences were processed using Qiime 1.8. Paired
end reads were quality filtered using a Q30 cutoff, and
chimeric sequences identified using the USEARCH method
against the Greengenes alignment (version 13_8) were
removed. OTUs were picked at 97% similarity using the
UCLUST method, and representative sequences were assigned
taxonomies using the RDP classifier. Principle component
analysis of the relative abundances of taxa identified up to the
genus level for Balb/c, Balb/c Ach, Balb/c B and Balb/c Bch.
Whole genome sequencing and analysis
For whole genome sequencing, genomic DNA was extracted
from 100 mg of fresh liver tissue using the DNeasy Tissue kit
(Qiagen) following the manufacturer instructions. Briefly, each
liver tissue sample was lysed with proteinase K and lysis buffer
and incubated over night at 55°C, the lysed tissue was then
loaded onto a DNeasy spin columns with a silica-gel
membrane, washed and eluted in 100 lL elution buffer. DNA
yield was assessed using the QuantusTM fluorometer (Promega)
and DNA quality was measured using the Nanodrop ND-1000
spectrophotometer (Thermofisher). A quantity of 1 lg of liver
DNA was sheared and then PE sequencing libraries were
constructed using an Illumina TruSeq DNA Sample Preparation
kit (Thermofisher) according to the manufacturer’s
recommended protocol. The library was quantified using Qubit
fluorometry (Thermofisher) and sized on an Agilent Bioanalyser
DNA chip (Agilent Technologies, Santa Clara, CA, USA). The
resulting whole genome library was amplified on a flow cell
using an Illumina cBot cluster station (Illumina, San Diego,
CA, USA) and 350 million paired end reads at 125 bp length
were generated on an Illumina HiSeq 1000 at NZGL. The
sequences have been uploaded to the SRA database and are
awaiting approval, submission number SUB2635230.
Quality filtering was performed using trimmomatic with a
sliding window of 10 nt, quality ≥15 and read length ≥120 nt
(Bolger Bioinf, 2014). The remaining high quality reads were
mapped at 99% similarity to the mouse reference genome
(GRCm38.p5) using BBMap with default parameters
(https://sourceforge.net/projects/bbmap/). SNP and INDEL
polymorphisms to the reference genome (GRCm38.p5) were
called using samtools and bcftools.60 Variants were filtered
using a custom Ruby script keeping only those with a score
>100, >10 reads mapped to the variant allele, >10 nt to each
other and not present in the other line (A vs B) to give list of
polymorphisms specific to BALB/c A and a list specific to
BALB/c B. Mutations existed throughout the genome and
were assigned to neighboring genes if not in coding sequence
using a custom Perl script that matched the genomic position
of the variant to genes described in the genome feature table
GCF_000001635.25_GRCm38.p5 from ensemble.
Bioinformatic analysis was performed to identify a list of
previously reported relevant genes in signaling pathways (KEGG
pathway database mmu04662, mmu04620, mmu04630,
mmu04151, mmu04064, mmu04115). Gene ontology assignment
to variant genes was performed with the MGI database. Immgen
was used to assess expression patterns (Gene skyline database, key
populations and B cell data group). The predicted effect of
polymorphisms was determined using various databases: genome
location: MGI mouse genome browser (Jbrowse), VEGA gene
model and NCBI databases; splicing prediction: Human splice
finder, AAS sites and Sroogle61,62; regulatory region location:
ORegAnno within UCSC Genome Browser Mouse Dec. 2011
(GRCm38/mm10) genome assembly; and transcription factor
binding: Transfac databases (vertebrate_non_redundant_minFP
and immune_specific).
Statistical analysis
Single comparisons were made using the Mann–Whitney U-test
unless otherwise stated. All statistical analyses were performed
using GraphPad Prism v6: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
and ****P ≤ 0.0001.
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